Not necessarily the strongest absolute response. The most rational target could be the one where the difference in efficacy between Coramsine and the current best treatment is greatest. This presumably needs also to be blended with market potential to arrive at the optimal target.
- Forums
- ASX - By Stock
- genentech up $11 billion
SBP
solbec pharmaceuticals limited
Not necessarily the strongest absolute response. The most...
Add SBP (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
ACW
ACTINOGEN MEDICAL LIMITED
Steven Gourlay, Managing Director and CEO
Steven Gourlay
Managing Director and CEO
Previous Video
Next Video
SPONSORED BY The Market Online